875781-18-3

Basic information

• Product Name: 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine
• Synonyms: 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine;2-bromo-7-iodo-5H-pyrrolo[3,2-b]pyrazine ;5-Bromo-3-iodo-1H-pyrazol...;5-broMo-3-iodo-1H-pyrazolo[3;3-iodo-5-broMo-1H-pyrazolo[3,4-b]pyridine;5-broMo-3-iodo-1H-pyrazolo[3,4-b]pyrazine;1H-Pyrazolo[3,4-b]pyridine,5-bromo-3-iodo-;5-bromo-3-iodo-2H-pyrazolo[3,4-b]pyridine
• CAS NO: 875781-18-3
• Molecular Formula: C₆H₃BrIN₃
• Molecular Weight: 323.92
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyridine series
• Mol File: 875781-18-3.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 409.1 °C at 760 mmHg
• Flash Point: 201.2 °C
• Appearance: /
• Density: 2.559
• Vapor Pressure: 1.57E-06mmHg at 25°C
• Refractive Index: 1.824
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.70±0.40(Predicted)
• CAS DataBase Reference: 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine(875781-18-3)
• EPA Substance Registry System: 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine(875781-18-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 875781-18-3(Hazardous Substances Data)

Usage

General Description

5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine is a chemical compound with the molecular formula C8H5BrIN3. It is a heterocyclic compound that contains both bromine and iodine atoms. 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine is commonly used in organic synthesis and medicinal chemistry as a building block for creating more complex molecules. It is also used as a reagent in various chemical reactions due to its unique structural properties. Additionally, 5-bromo-3-iodo-1H-pyrazolo[3,4-b]pyridine has potential pharmaceutical applications and is being studied for its potential as a drug candidate for the treatment of various diseases. Overall, this compound is an important and versatile chemical in the field of organic chemistry and drug discovery.

InChI:InChI=1/C6H3BrIN3/c7-3-1-4-5(8)10-11-6(4)9-2-3/h1-2H,(H,9,10,11)

Upstream product

• 875781-15-0 5-bromo-2-fluoro-3-pyridinecarboxaldehyde 
• 516-12-1 N-iodo-succinimide 
• 875781-17-2 5-bromo-7-azaindazole 
• 271-73-8 1H-Pyrazolo[3,4-b]pyridine 
• 117007-52-0 3-iodo-1H-pyrazolo[3,4-b]pyridine 

Downstream Products

• 1421685-07-5 C₃₂H₃₁F₃N₆O 
• 1421685-06-4 C₃₀H₂₉F₃N₆O 
• 1421685-08-6 C₃₅H₃₁F₃N₆O 
• 1431221-13-4 C₃₈H₄₅F₃N₆O₂Si 
• 1448705-58-5 C₃₆H₄₃F₃N₆O₂Si 
• 1186608-72-9 5-bromo-3-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine 
• 882029-94-9 5-bromo-3-phenyl-1H-pyrazolo[3,4-b]pyridine 
• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 

Relevant articles and documents

Azaindazole bipyridine derivative myeloid cell proliferation inhibitor as well as preparation method and application thereof in pharmacy

The invention provides an azaindazole bipyridine derivative myeloid cell proliferation inhibitor shown as a formula I, wherein R1, R2 and R3 have the meanings defined in the specification of the invention. A compound in formula I can significantly inhibit proliferation and related disordersof myeloid cells represented by MOLM-16, HL-60, and MV-4-11. The formula I or salt thereof or the related pharmaceutical composition provided by the invention has excellent in-vivo and in-vitro inhibitory activity, good druggability, high bioavailability and no obvious damage to organs. Therefore, the compound shown in the formula I or the salt thereof and the related drug combination have huge clinical application prospects.

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

HETEROARYL-SUBSTITUTED PYRAZOLO-PYRIDINE PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.